Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Azathioprine Induced Severe Myelosuppression and Alopecia Totalis in IgA Nephropathy

  • Kim, Jae Choon (Departments of Pediatrics, Seoul National University Children's Hospital) ;
  • Kim, Ye Kyung (Departments of Pediatrics, Seoul National University Children's Hospital) ;
  • Hyun, Hye Sun (Departments of Pediatrics, Seoul National University Children's Hospital) ;
  • Park, Eu Jin (Departments of Pediatrics, Seoul National University Children's Hospital) ;
  • Kang, Hee Gyung (Departments of Pediatrics, Seoul National University Children's Hospital) ;
  • Ha, Il Soo (Departments of Pediatrics, Seoul National University Children's Hospital) ;
  • Cheong, Hae Il (Departments of Pediatrics, Seoul National University Children's Hospital)
  • Received : 2017.03.17
  • Accepted : 2017.03.31
  • Published : 2017.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Azathioprine is commonly used as immunosuppressive therapy for various inflammatory diseases including chronic glomerulonephritis. Myelosuppression is a common side effect of azathioprine, resulting in the need for dose reduction. However, severe pancytopenia or alopecia is not often encountered. Here, we report a case of severe myelosuppression, and alopecia totalis that occurred after azathioprine treatment in a patient with IgA nephropathy. A 10-year-old boy with IgA nephropathy was treated with oral deflazacort and later with azathioprine. After 4 weeks, the patient complained of hair loss, and despite a dose reduction in azathioprine, he developed bone marrow suppression and alopecia totalis in two weeks. The blood indices and alopecia of the patient had returned to normal after azathioprine withdrawal and 3 consecutive doses of granulocyte colony-stimulating factor. We suggest that physicians remain vigilant to the side effects of azathioprine. Unusual hair loss after azathioprine treatment might suggest a defect in the metabolism of the drug, warranting the discontinuation of azathioprine to prevent more severe side effects.

Keywords

References

  1. Derijks L, Gilissen L, Hooymans P, Hommes D. Review article: thiopurines in inflammatory bowel disease. Alimentary pharmacology & therapeutics 2006;24:715-29. https://doi.org/10.1111/j.1365-2036.2006.02980.x
  2. Mertens H, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Annals of the New York Academy of Sciences 1981;377:691-9. https://doi.org/10.1111/j.1749-6632.1981.tb33767.x
  3. Anstey A, Lennard L, Mayou S, Kirby J. Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism: a review. Journal of the Royal Society of Medicine 1992;85:752.
  4. Collie-Duguid E, Sludden J, Li T, McLeod H. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics and Genomics 1999; 9:37-42. https://doi.org/10.1097/00008571-199902000-00006
  5. Lee YJ, Hwang EH, Park JH, Shin JH, Kang B, Kim SY. NUDT15 variant is the most common variant associated with thiopurineinduced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease. Eur J Gastroenterol Hepatol 2016;28: 475-8.
  6. Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis & Rheumatology 1975;18:27-34. https://doi.org/10.1002/art.1780180106
  7. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease. Clinical pharmacokinetics 2007;46:187-208. https://doi.org/10.2165/00003088-200746030-00001
  8. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical Pharmacology & Therapeutics 1989;46:149-54. https://doi.org/10.1038/clpt.1989.119
  9. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. The American journal of gastroenterology 2008;103:1783-800. https://doi.org/10.1111/j.1572-0241.2008.01848.x
  10. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroen terology 1998;115:813-21. https://doi.org/10.1016/S0016-5085(98)70251-3
  11. O'Donoghue D, Dawson A, Powell-Tuck J, Bown R, Lennard-Jones J. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. The Lancet 1978;312:955-7. https://doi.org/10.1016/S0140-6736(78)92524-2
  12. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of gastroenterology and hepatology 2005;20: 1149-57. https://doi.org/10.1111/j.1440-1746.2005.03832.x
  13. Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepato-gastroenterology 2005;53:399-404.
  14. DiPiero J, Teng K, Hicks JK. Should thiopurine methyltransferase (TPMT) activity be determined before prescribing azathioprine, mercaptopurine, or thioguanine? Cleveland Clinic journal of medicine 2015;82:409-13. https://doi.org/10.3949/ccjm.82a.14106
  15. Yang S-K, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nature genetics 2014;46:1017-20. https://doi.org/10.1038/ng.3060
  16. Kakuta Y, Naito T, Onodera M, Kuroha M, Kimura T, Shiga H, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. The Pharmacogenomics Journal 2016;16:280-5. https://doi.org/10.1038/tpj.2015.43
  17. Yu Y, Cai J-P, Tu B, Wu L, Zhao Y, Liu X, et al. Proliferating cell nuclear antigen is protected from degradation by forming a complex with MutT Homolog2. Journal of Biological Chemistry 2009;284: 19310-20. https://doi.org/10.1074/jbc.M109.015289